Literature DB >> 17614245

Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.

P Del Bianco1, G Zavagno, P Burelli, G Scalco, L Barutta, P Carraro, P Pietrarota, G Meneghini, T Morbin, G Tacchetti, P Pecoraro, V Belardinelli, G L De Salvo.   

Abstract

AIMS: To compare physical morbidity and health-related quality of life (HRQOL) in breast cancer patients who received standard axillary dissection (ALND) or sentinel lymph node biopsy (SLNB), followed by axillary dissection only in the case of sentinel-node positivity, within a randomised clinical trial. PATIENTS AND METHODS: Patients with early breast cancer < or =3cm and clinically negative axilla were randomly allocated to ALND or SLNB. All patients underwent physical examination every 6 months in order to assess any arm-related symptoms. A subset of patients completed the SF-36 quality of life questionnaire and the Psychological General Well Being Index (PGWBI) before randomisation, at 6 and 12 months after surgery and yearly thereafter. Results of the first 24 months are reported.
RESULTS: Six-hundred and seventy-seven patients were available for analysis: 341 patients randomised to the ALND group and 336 to the SLNB group. Six months after surgery, the SLNB group had significantly less lymph-oedema, movement restrictions, pain and numbness with respect to the ALND group. Lymph-oedema was also significantly reduced at 12 months and numbness remained significantly less frequent in the SLNB arm at all time points. Three-hundred and ten patients participated in the HRQOL assessment. The mean scores of the PGWB questionnaire general index and anxiety domain were significantly better in the SLNB group than in the ALND group but the difference ceased to be significant at 24 months.
CONCLUSIONS: The SLNB is associated with reduced arm morbidity without evidence of a negative impact on psychological well being. While waiting for long-term results of ongoing randomised clinical trials, the SLNB may be proposed for early stage breast cancer patients after adequate information on the expected advantages and the possible risks.

Entities:  

Mesh:

Year:  2007        PMID: 17614245     DOI: 10.1016/j.ejso.2007.05.017

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  44 in total

1.  Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.

Authors:  Takamaru Ashikaga; David N Krag; Stephanie R Land; Thomas B Julian; Stewart J Anderson; Ann M Brown; Joan M Skelly; Seth P Harlow; Donald L Weaver; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years.

Authors:  Yoshinari Ogawa; Katsumi Ikeda; Kana Ogisawa; Shinya Tokunaga; Hiroko Fukushima; Takeshi Inoue; Yoshihiro Mori; Akiko Tachimori; Toru Inoue; Yukio Nishiguchi
Journal:  Surg Today       Date:  2013-09-26       Impact factor: 2.549

Review 3.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

4.  Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.

Authors:  Stephanie R Land; Jacek A Kopec; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Nicholas J Christian; Joseph P Costantino; Norman Wolmark; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

5.  Quality of life among a population-based cohort of older patients with breast cancer.

Authors:  Joan M Neuner; Nathan Zokoe; Emily L McGinley; Liliana E Pezzin; Tina W F Yen; Marilyn M Schapira; Ann B Nattinger
Journal:  Breast       Date:  2014-07-14       Impact factor: 4.380

Review 6.  Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities.

Authors:  Mohammed Keshtgar; John J Zaknun; Durre Sabih; Graciela Lago; Charles E Cox; Stanley P L Leong; Giuliano Mariani
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

7.  A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection.

Authors:  Jan J Kootstra; Josette E H M Hoekstra-Weebers; Johan S Rietman; Jakob de Vries; Peter C Baas; Jan H B Geertzen; Harald J Hoekstra
Journal:  Ann Surg Oncol       Date:  2010-03-11       Impact factor: 5.344

8.  Predicting Non-sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population with 1-2 Positive Sentinel Nodes: Development and Assessment of a New Predictive Nomogram.

Authors:  Jia-ying Chen; Jia-jian Chen; Jing-yan Xue; Ying Chen; Guang-yu Liu; Qi-xia Han; Wen-tao Yang; Zhen-zhou Shen; Zhi-min Shao; Jiong Wu
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

Review 9.  Breast cancer in young women and its impact on reproductive function.

Authors:  M Hickey; M Peate; C M Saunders; M Friedlander
Journal:  Hum Reprod Update       Date:  2009-01-27       Impact factor: 15.610

10.  Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma.

Authors:  Mattijs de Vries; Harald J Hoekstra; Josette E H M Hoekstra-Weebers
Journal:  Ann Surg Oncol       Date:  2009-07-29       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.